🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the effort against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Public Health Issue

Gonorrhoea infections are increasing globally, with data suggesting more than 82 million infections annually. Especially elevated rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an important and timely advancement in the face of growing infection rates, escalating drug resistance and the very limited treatment choices at this time.”

Public health authorities are increasingly worried about the surge in treatment-resistant strains. The WHO has listed it as a "critical concern". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Secure Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This treatment, which is also used to treat UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This approval represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Research Study Outcomes and Worldwide Availability

As per findings published in a prominent scientific publication, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The study included hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the ability to license and sell the drug in numerous developing nations.

Clinicians on the front lines have shared hope. The availability of a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for managing the epidemic. This is viewed as vital to alleviate the strain of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.